Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Rabaglio M, Thürlimann B, Colleoni M, Goldhirsch A, Gelber R, Coates A, Castiglione M, Ruepp B, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Giobbie-Hurder A, Maibach R, Sun Z, Regan M. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Res Treat 2020
Nov 7, 2020Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Nov 7, 2020Breast Cancer Res Treat 2020
Rabaglio Manuela, Thürlimann Beat, Colleoni Marco, Goldhirsch Aron, Gelber Richard D, Coates Alan S, Castiglione Monica, Ruepp Barbara, Wardley Andrew, Bonnefoi Hervé, Láng István, Neven Patrick, Harvey Vernon J, Ejlertsen Bent, Giobbie-Hurder Anita, Maibach Rudolf, Sun Zhuoxin, Regan Meredith M
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer
Tesch H, Luftner D, Schneeweiss A, Lux M, Fehm T, Overkamp F, Welslau M, Schulmeyer C, Kolberg H, Fasching P, Huober J, Thill M, Hartkopf A, Schütz F, Belleville E, Ettl J, Wöckel A, Müller V, Janni W. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80:1115-1122.
Nov 6, 2020Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer
Nov 6, 2020Geburtshilfe Frauenheilkd 2020; 80:1115-1122
Tesch Hans, Luftner Diana, Schneeweiss Andreas, Lux Michael P, Fehm Tanja N, Overkamp Friedrich, Welslau Manfred, Schulmeyer Carla E, Kolberg Hans-Christian, Fasching Peter A, Huober Jens, Thill Marc, Hartkopf Andreas, Schütz Florian, Belleville Erik, Ettl Johannes, Wöckel Achim, Müller Volkmar, Janni Wolfgang
Update Breast Cancer 2020 Part 3 - Early Breast Cancer
Huober J, Schütz F, Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Schulmeyer C, Kolberg H, Fasching P, Thill M, Belleville E, Ettl J, Janni W, Lux M, Müller V, Hartkopf A, Schneeweiss A, Wöckel A. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80:1105-1114.
Nov 6, 2020Update Breast Cancer 2020 Part 3 - Early Breast Cancer
Nov 6, 2020Geburtshilfe Frauenheilkd 2020; 80:1105-1114
Huober Jens, Schütz Florian, Luftner Diana, Fehm Tanja N, Tesch Hans, Overkamp Friedrich, Welslau Manfred, Schulmeyer Carla E, Kolberg Hans-Christian, Fasching Peter A, Thill Marc, Belleville Erik, Ettl Johannes, Janni Wolfgang, Lux Michael P, Müller Volkmar, Hartkopf Andreas D, Schneeweiss Andreas, Wöckel Achim
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors
Gachechiladze M, Škarda J, Bouchalova K, Soltermann A, Jörger M. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors. Front Oncol 2020; 10:581217.
Nov 3, 2020Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors
Nov 3, 2020Front Oncol 2020; 10:581217
Gachechiladze Mariam, Škarda Josef, Bouchalova Katerina, Soltermann Alex, Jörger Markus
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunol Immunother 2020
Nov 1, 2020SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Nov 1, 2020Cancer Immunol Immunother 2020
Mark Michael, Früh Martin, Biaggi-Rudolf Christine, Weindler Susanne, Baudoux Nathalie, Schwitter Michael, Wannesson Luciano, Jörger Markus, Metaxas Yannis, Schneider Martina, Friedlaender Alex, Burmeister Henning, Janthur Wolf-Dieter, Rothschild Sacha I, Pless Miklos, Addeo Alfredo, Eboulet Eric Innocents, Froesch Patrizia, Swiss Group for Clinical Cancer Research (SAKK)
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Di Cosimo S, Daidone M, Piccart M, Izquierdo M, Fumagalli D, Huober J, Saura C, De Santis M, Franzoi M, Cinieri S, Agbor-Tarh D, Porcu L, de Azambuja E. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res 2020; 22:115.
Oct 27, 2020Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Oct 27, 2020Breast Cancer Res 2020; 22:115
Di Cosimo Serena, Daidone Maria Grazia, Piccart Martine, Izquierdo Miguel, Fumagalli Debora, Huober Jens, Saura Cristina, De Santis Maria Carmen, Franzoi Maria Alice, Cinieri Saverio, Agbor-Tarh Dominique, Porcu Luca, de Azambuja Evandro
To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
Herbert S, Schwentner L, Fink V, Bekes I, Leinert E, Lato K, Polasik A, Schochter F, Singer S, Salmen J, Diessner J, Stüber T, Wöckel A, Kreienberg R, Kühn T, Flock F, Felberbaum R, Janni W, Curtaz C, Kiesel M, BRENDA study group. To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?. Breast Cancer Res Treat 2020; 185:677-684.
Oct 26, 2020To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
Oct 26, 2020Breast Cancer Res Treat 2020; 185:677-684
Herbert S L, Schwentner L, Fink V, Bekes Inga, Leinert E, Lato K, Polasik A, Schochter F, Singer S, Salmen J, Diessner J, Stüber T, Wöckel A, Kreienberg R, Kühn T, Flock F, Felberbaum R, Janni W, Curtaz C, Kiesel M, BRENDA study group
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res 2020; 22:111.
Oct 23, 2020Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
Oct 23, 2020Breast Cancer Res 2020; 22:111
De Gregorio Amelie, Schneeweiss Andreas, Tesch Hans, Mahner Sven, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Lato Krisztian, Beckmann Matthias W, Rack Brigitte, Andergassen Ulrich, Bekes Inga, Fink Visnja, Häberle Lothar, Fasching Peter A, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Friedl Thomas W P, Bauer Emanuel, De Gregorio Nikolaus, Deniz Miriam, Janni Wolfgang
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Fasching P, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R, Hahnen E, Untch M, Burchardi N, Blohmer J, Loibl S, Doering G, Uleer C, Schmitt W, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 2020; 32:49-57.
Oct 21, 2020Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Oct 21, 2020Ann Oncol 2020; 32:49-57
Fasching P A, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R K, Hahnen E, Untch M, Burchardi N, Blohmer J-U, Loibl S, Doering G, Uleer C, Schmitt W D, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober Jens, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast
A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies
Schaerer D, Froehlich T, Hamzic S, Offer S, Diasio R, Jörger M, Amstutz U, Largiadèr C. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. J Pers Med 2020; 10
Oct 19, 2020A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies
Oct 19, 2020J Pers Med 2020; 10
Schaerer Dominic, Froehlich Tanja K, Hamzic Seid, Offer Steven M, Diasio Robert B, Jörger Markus, Amstutz Ursula, Largiadèr Carlo R
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020; 12
Oct 17, 2020Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Oct 17, 2020Cancers (Basel) 2020; 12
Michel Laura L, Hielscher Carsten, Mundhenke Christoph, Kurbacher Christian, Wuerstlein Rachel, Untch Michael, Overkamp Friedrich, Huober Jens, Janni Wolfgang, Taran Florin-Andrei, Lux Michael P, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Wimberger Pauline, Huebner Hanna, Hartkopf Andreas D, Fasching Peter A, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Volz Bernhard, Fehm Tanja N
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2020; 26:e53-e65.
Oct 9, 2020Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Oct 9, 2020Oncologist 2020; 26:e53-e65
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors
Ojara F, Henrich A, Frances N, Huisinga W, Hartung N, Jörger M, Kloft C. Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. J Pharmacol Exp Ther 2020; 375:430-438.
Oct 2, 2020Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors
Oct 2, 2020J Pharmacol Exp Ther 2020; 375:430-438
Ojara Francis W, Henrich Andrea, Frances Nicolas, Huisinga Wilhelm, Hartung Niklas, Jörger Markus, Kloft Charlotte
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Schmid S, De Giorgi U, Hansen A, Beer T, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Bianchini D, Chi K, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen M, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open 2020; 3:e2021692.
Oct 1, 2020Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Oct 1, 2020JAMA Netw Open 2020; 3:e2021692
Schmid Sabine, De Giorgi Ugo, Hansen Aaron R, Beer Tomasz M, Lavaud Pernelle, Morales-Barrera Rafael, Tucci Marcello, Castro Elena, Karalis Kostas, Bergman Andries M, Le Mo Linh, Zürrer-Härdi Ursina, Pezaro Carmel, Suzuki Hiroyoshi, Zivi Andrea, Klingbiel Dirk, Schär Sämi, Bianchini Diletta, Chi Kim N, Omlin Aurelius, Higano Celestia, Sweeney Christopher, Martinez Chanza Nieves, Mehra Niven, Kuppen Malou C P, Beltran Himisha, Conteduca Vincenza, Vargas Pivato de Almeida Daniel, Cotait Maluf Fernando, Oh William K, Tsao Che-Kai, Sartor Oliver, Ledet Elisa, Di Lorenzo Giuseppe, Yip Steven M, Gillessen Silke
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Hamilton E, Johnston E, Bear M, Hardebeck M, Lu Y, Chapman S, Huober J, Hegg R, Jerusalem G, Manikhas A, Petrakova K, Chen S, Ozyilkan O, Cortes J, Martín M. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clin Breast Cancer 2020
Sep 30, 2020nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Sep 30, 2020Clin Breast Cancer 2020
Hamilton Erika, Johnston Erica L, Bear Melissa M, Hardebeck Molly C, Lu Yi, Chapman Sonya C, Huober Jens, Hegg Roberto, Jerusalem Guy, Manikhas Aleksey, Petrakova Katarina, Chen Shin-Cheh, Ozyilkan Ozgur, Cortes Javier, Martín Miguel
MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clin Cancer Res 2020; 27:179-188.
Sep 23, 2020MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Sep 23, 2020Clin Cancer Res 2020; 27:179-188
Wirsching Hans-Georg, Tabatabai Ghazaleh, Ochsenbein Adrian, Roth Patrick, Remonda Luca, Conen Katrin, Caparrotti Francesca, von Moos Roger, Hottinger Andreas F, Hundsberger Thomas, Weller Jonathan, Roelcke Ulrich, Weller Michael
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston S, Huober J, Wardley A, Tolaney S, Cicin I, Smith I, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, Cortes J, Neven P, Harbeck N, Hegg R, Toi M, Martín M, Shao Z, Zhang Q, Martinez Rodriguez J, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38:3987-3998.
Sep 20, 2020Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Sep 20, 2020J Clin Oncol 2020; 38:3987-3998
Johnston Stephen R D, Huober Jens, Wardley Andrew, Tolaney Sara M, Cicin Irfan, Smith Ian C, Frenzel Martin, Headley Desirée, Wei Ran, San Antonio Belen, Hulstijn Maarten, Cox Joanne, O'Shaughnessy Joyce, Rastogi Priya, Cortes Javier, Neven Patrick, Harbeck Nadia, Hegg Roberto, Toi Masakazu, Martín Miguel, Shao Zhi Min, Zhang Qing Yuan, Martinez Rodriguez Jorge Luis, Campone Mario, Hamilton Erika, Sohn Joohyuk, Guarneri Valentina, Okada Morihito, Boyle Frances, monarchE Committee Members and Investigators
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54:88-95.
Aug 29, 2020Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Aug 29, 2020Breast 2020; 54:88-95
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Britschgi C, Banna G, Wild P, Rothschild S, Gautschi O, Banini M, Metro G, Früh M, Delaloye R, Rechsteiner M, Addeo A, Curioni-Fontecedro A. Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Front Oncol 2020; 10:1299.
Aug 21, 2020Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Aug 21, 2020Front Oncol 2020; 10:1299
Britschgi Christian, Banna Giuseppe L, Wild Peter J, Rothschild Sacha I, Gautschi Oliver, Banini Marco, Metro Giulio, Früh Martin, Delaloye Raphaël, Rechsteiner Markus, Addeo Alfredo, Curioni-Fontecedro Alessandra
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Mateos M, Mohty M, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hájek R, Dimopoulos M, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2020; 35:31-44.
Aug 19, 2020Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Aug 19, 2020Leukemia 2020; 35:31-44
Ludwig Heinz, Einsele Hermann, Delforge Michel, Caers Jo, Weisel Katja, Jackson Graham, Garderet Laurent, Engelhardt Monika, van de Donk Niels, Leleu Xavier, Goldschmidt Hartmut, Beksac Meral, Nijhof Inger, Abildgaard Niels, Bringhen Sara, Mateos Maria-Victoria, Mohty Mohamad, Boccadoro Mario, Moreau Philippe, San-Miguel Jesus, Cavo Michele, Pawlyn Charlotte, Zweegman Sonja, Facon Thierry, Driessen Christoph, Hájek Roman, Dimopoulos Melitios A, Gay Francesca, Avet-Loiseau Hervé, Terpos Evangelos, Zojer Niklas, Sonneveld Pieter